- GlobeNewswire•2 days ago
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
SALT LAKE CITY and BOULDER, Colo., April 27, 2017-- Myriad Genetics, Inc. and Clovis Oncology, Inc. today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment ...
- Motley Fool•3 days ago
Has the market overestimated the odds of success for Tesaro's fancy new cancer drug?
- Motley Fool•8 days ago
Tesaro has set the price of its newly launched PARP inhibitor, Zejula, at nearly $10,000 per month.
CLVS : Summary for Clovis Oncology, Inc. - Yahoo Finance
Clovis Oncology, Inc. (CLVS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||54.00 x 100|
|Ask||58.11 x 400|
|Day's Range||56.76 - 59.24|
|52 Week Range||11.57 - 74.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.38|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|